These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22777274)

  • 1. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.
    Asimakopoulos AD; Cerruto MA; Del Popolo G; La Martina M; Artibani W; Carone R; Finazzi-Agrò E
    Urol Int; 2012; 89(3):259-69. PubMed ID: 22777274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
    Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
    BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Schaefer W
    Int J Urol; 2007 Jul; 14(7):670; author reply 670-1. PubMed ID: 17645621
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.
    Moon HS; Lee JW; Park SY; Son YW; Kim YT
    Urology; 2010 Aug; 76(2):509.e8-12. PubMed ID: 20546876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies for medical management of overactive bladder in children.
    Schröder A; Thüroff JW
    Curr Opin Urol; 2010 Jul; 20(4):313-7. PubMed ID: 21475074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
    Chapple CR; Khullar V; Gabriel Z; Muston D; Bitoun CE; Weinstein D
    Eur Urol; 2008 Sep; 54(3):543-62. PubMed ID: 18599186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
    Grigoleit U; Mürtz G; Laschke S; Schuldt M; Goepel M; Kramer G; Stöhrer M
    Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
    Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
    BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.